# MOCK – DCRI Master Services Agreement: Northstar Therapeutics (Phase II CV Outcomes)

This is a MOCK sample for tooling tests. No real data.

This Study Site Agreement (the “**Agreement**”) is entered into as of the date of the last signature hereon, (the “**Effective Date**”) by and between Duke University, a tax-exempt research and educational institution located in Durham, North Carolina, acting for and on behalf of its Duke Clinical Research Institute (“**Duke**”)” and \_\_\_\_\_\_\_\_\_\_\_\_\_, located at \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (“**Study Site**”) Duke and Study Site may be referred to herein each as a “Party” and collectively the “Parties”.

**Performance of Study:**

* 1. Study Site agrees to conduct this Study in strict accordance with the Protocol (as it may be amended from time to time by the Sponsor), all applicable local, state, and federal guidelines relevant to the conduct of clinical protocols that are reflected in US state and federal regulations, including, but not limited to the Federal Food, Drug and Cosmetic Act and regulations of the United States Food and Drug Administration (“**FDA**”), the Health Insurance Portability and Accountability Act of 1996, as amended (“**HIPAA**”**)**, and the Guidelines for Good Clinical Practice adopted by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (“ICH GCP”), E6, to the extent adopted by the FDA, conditions imposed by the Study Site’s IRB and the written instructions of the Sponsor and Duke relative to the administration of the Protocol. The Parties agree to comply with and to conduct the Study in accordance with all applicable federal, state and local laws and regulations. All the terms of the Protocol and any further amendments to the Protocol are incorporated hereunder and are part of this Agreement.

2. **Payment/Funds Availability/Reimbursement:**

2.1 In consideration of the work to be performed under this Agreement, Sponsor through its third-party vendor (“**Payment Administrator**”), will provide financial support for the Study as set forth in the Budget and Payment Schedule attached hereto as **Exhibit B** and will provide such funds to Payment Administrator for the purpose of paying all compensation due Study Site pursuant to Exhibit B. Payment Administrator will administer such funds and shall make all payments to Study Site in accordance with the payment schedule included in Exhibit B. Study Site acknowledges and agrees Payment Administrator will have access to this Agreement in order to issue payments.

2.2 If the Protocol is amended and such amendment causes a change to the Study procedures conducted, which requires a modification to the Study Budget due to increased costs to Study Site, the Parties agree to negotiate in good faith and execute an amendment to Exhibit B to account for such changes.

Parties: Duke Clinical Research Institute (DCRI) and Northstar Therapeutics, Inc.

Effective Date: September 15, 2025

Study: Phase II, randomized, double‑blind CV outcomes sub‑study for NST‑217.

Budget Summary (Proposed): Base Fee: $1,450,000; Per-Patient Fee: $9,800; Milestones: FPI 2025‑10‑20; IA 2026‑03‑01; DB Lock 2026‑08‑15.

Per‑patient unit rate:$9,800 proposed (floor $8,800 if scope reduced. We can flex down only if monitoring scope is reduced.).

Payment Terms:

Milestone: Database Lock Target:

Publication Review Period:60 days with single optional 30‑day extension for IP only.

First Patient In (FPI):2025‑10‑20(DCRI cannot start earlier than this without rush fees).